Veeva launches Falcon AI platform for drug development

Veeva has launched Falcon, an agentic artificial intelligence platform for drug development. The system is aimed at clinical, regulatory, and safety teams in life sciences.

Designed to work with Veeva's Development Cloud applications, Falcon automates tasks including trial master file document intake and quality control, health authority correspondence in regulatory work, and safety case triage and intake.

The launch puts Veeva among software providers seeking to apply AI agents to tightly regulated research and development work, where pharmaceutical and biotechnology companies face pressure to cut costs and shorten timelines without weakening compliance controls.

Falcon's initial scope focuses on three areas that are often labor-intensive and documentation-heavy. In clinical operations, that includes handling trial master file documents and checking them for quality issues. In regulatory affairs, the focus is correspondence with health authorities. In drug safety, the initial use cases cover safety case triage and intake.

Veeva is positioning Falcon as part of a broader AI push in life sciences. The platform sits within Veeva AI, its wider set of AI products for the industry, and is expected to be available to early adopters from November 2026.

That timeline suggests the product is still in an early commercial phase, with Veeva seeking initial users before a broader rollout. It also indicates the company views agentic AI as a longer-term product line rather than a one-off addition to its existing software portfolio.

Regulated workflows

Applying AI to drug development has drawn interest across the sector because many core processes still depend on large volumes of manual review, document handling, and administrative routing. These tasks can create bottlenecks in clinical development, regulatory submissions, and pharmacovigilance operations.

At the same time, adoption in these areas has been slower than in less regulated corporate functions because companies must manage audit trails, data integrity, and oversight requirements. Any AI system used in these environments is likely to face close scrutiny over how decisions are made, how records are handled, and where human review remains necessary.

Veeva did not provide further technical detail on how Falcon's agents operate, but said the platform is intended to help life sciences companies improve efficiency while maintaining compliance. Falcon is designed for biopharma groups of different sizes.

Veeva has built its business around cloud software tailored to pharmaceutical and biotechnology companies and serves more than 1,500 customers, from large multinational drugmakers to smaller biotech groups. That installed base gives it a direct route into development, regulatory, and safety teams already using its software.

Competitive pressure

Falcon's debut comes as software groups and drug companies test how generative AI and related agent-based systems can be used beyond basic search, summarization, or drafting tools. Interest has shifted toward software that can take on structured tasks within existing workflows, particularly in areas where teams must process large volumes of repeatable work.

For Veeva, that creates an opening to add AI features to core systems customers already use, while also raising questions about reliability, accountability, and measurable savings. In regulated settings, buyers are likely to focus on whether such products can reduce manual effort without creating new compliance risks.

Peter Gassner, Founder and Chief Executive Officer of Veeva, described Falcon as a major product effort for the company.

"Falcon is a major initiative for Veeva and our first offering in agentic labor," said Peter Gassner, Founder and Chief Executive Officer of Veeva. "I'm excited to partner with customers and help the industry lower costs and increase speed in drug development with Falcon."